Elevated FOXA1 Expression Indicates Poor Prognosis in Liver Cancer due to Its Effects on Cell Proliferation and Metastasis

Table 1

Clinicopathological parameters of 374 hepatocellular carcinoma patients in TCGA database.

Characteristic	Low expression of FOXA1	High expression of FOXA1
	187	187
Gender, (%)			<0.001
Female	42 (11.2%)	79 (21.1%)
Male	145 (38.8%)	108 (28.9%)
Race, (%)			0.936
Asian	81 (22.4%)	79 (21.8%)
Black or African American	9 (2.5%)	8 (2.2%)
White	91 (25.1%)	94 (26%)
Age, (%)			0.011
≤60	76 (20.4%)	101 (27.1%)
>60	111 (29.8%)	85 (22.8%)
AFP (ng/ml), (%)			0.043
≤400	119 (42.5%)	96 (34.3%)
>400	26 (9.3%)	39 (13.9%)
T stage, (%)			0.109
T1	102 (27.5%)	81 (21.8%)
T2	42 (11.3%)	53 (14.3%)
T3	37 (10%)	43 (11.6%)
T4	4 (1.1%)	9 (2.4%)
N stage, (%)			1.000
N0	132 (51.2%)	122 (47.3%)
N1	2 (0.8%)	2 (0.8%)
M stage, (%)			1.000
M0	140 (51.5%)	128 (47.1%)
M1	2 (0.7%)	2 (0.7%)
Pathologic stage, (%)			0.280
Stage I	96 (27.4%)	77 (22%)
Stage II	42 (12%)	45 (12.9%)
Stage III	37 (10.6%)	48 (13.7%)
Stage IV	3 (0.9%)	2 (0.6%)
Vascular invasion, (%)			0.452
No	109 (34.3%)	99 (31.1%)
Yes	52 (16.4%)	58 (18.2%)